FDA grants Breakthrough Therapy designation to pexidartinib

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted Breakthrough Therapy Designation to pexidartinib (formerly PLX3397) for the treatment of tenosynovial giant cell tumor where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.

Currently, there is no FDA-approved systemic therapy for the treatment of TGCT. The designation was granted based on results from an extension cohort of a single-arm, multi-center phase I study that assessed the safety and efficacy of pexidartinib. Results of this study were published in The New England Journal of Medicine.

A pivotal phase III trial of pexidartinib called ENLIVEN is currently enrolling patients with symptomatic TGCT for whom surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.

Pexidartinib is an oral small molecule that potently and selectively inhibits colony stimulating factor-1 receptor, which is a primary growth driver of abnormal cells in the synovium that causes TGCT. Pexidartinib has not been approved by FDA or any other regulatory authority for uses under investigation.

In addition to Breakthrough Therapy Designation, pexidartinib has been granted Orphan Drug Designation by FDA for the treatment of PVNS and GCT-TS. Pexidartinib also has received Orphan Designation from the European Commission for the treatment of TGCT. Pexidartinib is sponsored by Daiichi Sankyo Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login